GNTA

Genenta Science (GNTA)

About Genenta Science (GNTA)

Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. Its lead product candidate, Temferon, was developed using its platform and carries an interferon-alpha payload. The company was founded by Pierluigi Paracchi, Luigi Naldini and Bernhard Gentner on July 24, 2014 and is headquartered in Milan, Italy.

Details

Daily high

Daily low

Price at open

52 Week High

$10.00

52 Week Low

$0.55

Market cap

31.2M

Dividend yield

0.00%

Volume

3,736

Avg. volume

79,220

P/E ratio

-3.58

Genenta Science News